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N ¼ 22 (%)
Median age at diagnosis 66.8
Male 12 (55)
PAD 13 (59)
CAD 13 (59)
CVA/TIA 5 (23)
HTN 17 (77)
CHF 5 (23)
Diabetes 9 (41)
Smoker 16 (76)
Thrombophilia 5 (23)
Atrial ﬁbrillation 4 (18)Early and Delayed Rupture after Endovascular Abdominal Aortic
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Objectives: Rupture after EVAR is a function of long-term graft dura-
bility and function. We describe our 10-year experience with rupture after
EVAR.
Methods: Between 2000 and 2010 1736 patients with AAA under-
went EVAR in a large, regional integrated health care system and 20 cases
of rupture after EVAR were identiﬁed. We examined risk factors associated
with “early” (<30 days after the initial EVAR) and “late” ($30 days
following the initial EVAR) rupture.
Results: The overall follow-up rate was 92%, and the median follow-
up was 2.7 years (IQR, 1.2-4.4 years). Among the 20 ruptures, 70% were
male, mean age was 79 years, AAA size at initial EVAR was 6.3 cm, and
6 patients underwent primary EVAR for rupture (n ¼ 3) or symptomatic
(n ¼ 3) presentation. Of the 20 ruptures after primary EVAR, 25% (5/
20) were “early” ruptures, all occurring within 2 days following the primary
EVAR. Of these 5 patients, 4 had intraoperative adverse events leading
directly to rupture, with 1 type I and 1 type III leak. Of the 5 “early”
ruptures, 4 underwent endovascular repair and 1 was repaired open, result-
ing in 2 perioperative deaths. Among the remaining 15 patients, the mean
time to “delayed” rupture was 36.6 6 27.5 months (Table). Most patients
had AAA sac increases prior to rupture with some patients having known
endoleaks or having undergone reintervention. At the time of delayed
rupture 12 of 15 patients were found to have new endoleaks. Six patients
did not undergo repair, while 9 underwent redo EVAR and 5 had open
repair.
For those patients who underwent repair for delayed rupture, survival
at 30 days and 1 year were 61.5% and 38.5%, respectively. Multivariate
analysis identiﬁed age >80 (HR, 3.5; CI, 1.1-11.0; P < .05), and urgent
EVAR (HR, 7.1; CI, 2.1-24.6; P <.01) as signiﬁcant predictors of delayed
rupture.
Conclusions: Rupture after EVAR is a rare but devastating event and
mortality after repair is high. The majority of delayed cases showed late AAA
expansion, thereby implicating acute device-related failures as the cause of
rupture in these patients and mandating vigilant surveillance. Future efforts
are needed to identify more sensitive predictors of rupture and graft dura-
bility after EVAR.Table.
Characteristics of 20 ru
Characteristic Early (n ¼ 5)
Sac expansion 0/5 (0%)
Known endoleak (type) 2/5, 40% (1 type 1, 1 typ
Endoleak at time of rupture (type) n ¼ 2 (1 type I, 1 type II
Prior attempt at endoleak repair 0
Endovascular repair at time of rupture
presentation
4/5 80%
Open repair at time of rupture presentation 1/5 (20%)
CMO status at time of rupture presentation 0/5
30-day survival 60%
1-year survival 40%
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Objectives: Acute aortic occlusion (AAO) is rare with the last large
series published in 1998 which included patients dating back to the
1980’s. These studies report that 50% of AAOs secondary to embolization
with an approximate mortality rate of 50%. We reviewed our recent experi-
ence with AAO to identify current etiologies and outcomes in a modern era.
Methods: CPT codes were used to identify patients with AAO from
2005-2012 from a prospectively maintained surgical database. AAOs
secondary to trauma, dissection or endograft occlusion were excluded.
Results: We identiﬁed 22 patients with AAO as outlined in Table.
Seventeen presented with isolated occlusion and ﬁve with occlusion extending
above the renal arteries. Signiﬁcant lower extremity neurologic deﬁcits were
noted in 12 patients, six with complete paralysis. Mean time from symptom
onset to diagnosis was 36 hours (range, 6-72 hours). 16 (73%) presented to our
institution as a transfer. Etiology was aortoiliac thrombosis in 17 (77%) cases,
embolic occlusion in 1, and indeterminate in 4. Extra-anatomic bypass was
performed in 14 patients, thromboembolectomy in 4 and aortobifemoral
bypass in3.Onepatientdiedprior to intervention.Acute renal failuredeveloped
in 14 patients (68%) and eight had rhabdomyolysis. Fasciotomywas performed
in 14 (68%) extremities and nine extremities required amputation (41%). All
cause mortality was 41% with all deaths occurring within 3 months of AAO.
Conclusions: AAO is an infrequent but devastating event. Our expe-
rience demonstrates that the etiology of AAO the etiology has shifted fromptures after EVAR
Delayed (n ¼ 15)
P value
(Fisher's exact)
13/15 (86%) .001
e 3) 6/15, 40% (2 type I, 5 type II, 1 type III
(some had more than one leak)
.99
I) n ¼ 12 (8 type I, 1 type II, 3 type III) .500
4/15 (26%) (1 redo EVAR, 3 angiograms) .233
9/15 (60%) .576
5/15 (33%) .516
6/15 (40%) .121
61.5% NS
38.5% NS
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Volume 58, Number 2 Abstracts 555embolic to aortoiliac thrombosis. Despite advances in vascular surgery over
the past decades, however, the morbidity and mortality remain signiﬁcant
with a high rate of limb loss, acute renal failure, rhabdomyolysis and death.
Contributing factors to poor outcomes continue to be delays in diagnosis
and the need for highly skilled tertiary centers.
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Objectives: Recent FDA approval of custom fenestrated endografts
has increased endovascular options for patients with short neck or juxtarenal
AAAs. We sought to compare the early learning curve at a single institution
of fenestrated repair versus the snorkel technique.
Methods: From 2009-2013 we performed 52 consecutive snorkel
procedures for juxtarenal AAAs in an IRB approved prospective cohort,
and since summer 2012 gained access to the FDA-approved custom fenes-
trated device. Patient demographics, imaging, and operative techniques
were compared between the ﬁrst 15 cases done for each of the Sn-EVAR
and f-EVAR techniques.
Results: Table summarizes the pre-, intra-, and postoperative data for
both techniques. Patient demographics and AAA morphology on preoper-
ative imaging were similar between the groups. Operative time tended to
be similar in the 3-4 hour range, with more ﬂuoroscopy time and less
contrast used on f-EVAR compared to Sn-EVAR (P < .05). Larger delivery
systems for f-EVAR required a much higher rate of iliac conduits.
Conclusion: A very similar technical skill set is necessary to success-
fully perform both Sn-EVAR and f-EVAR. A signiﬁcant portion of the
learning curve for both procedures FEVAR lies in the preoperative planning
of fenestrations and the cannulation of branch vessels. Similar patient and
operative outcomes between the two techniques early in the experience
indicates both techniques will likely have utility in the treatment of high-
risk patients with complex anatomy.Table.
Snorkel (n ¼ 15) FEVAR (n ¼ 15)
Age, years 75.8 77.4
Male/female 11/4 10/5
AAA size, cm 6.58 (5.5-8.4) 6.2 (4.7-10.5)
Target vessel success 24/24 27/28
Target vessel patency 24/24 25/28
Fluoroscopy time, minutes 66 99.1
Contrast, mL 170.5 123.4
EBL, mL 400 650
OR time, minutes 268.13 282
Median ICU LOS, days 1.0 (0-6) 1.5 (0-7)
Median total LOS, days 4 (2-10) 6 (4-24)
30-day mortality 0 0
Endoleaks
Type I 1 0
Type II 3/15 3/15
Type III 1/15 2/15
Iliac conduit 0/15 6/15
30-day reintervention 0/15 1/15
Table. AAA exclusion device OD guide
OD (Fr) per aortic neck diameter
18-22 mm 23-28 mm 29-32 mm
Contralateral
limb
Trivascular 14 (4.7 mm) 14 (4.7 mm) 14 (4.7 mm) 13-15
Endologix 17 (5.7 mm) 17 (5.7 mm) 17 (5.7 mm) 9
Medtronic 18 (6 mm) 20 (6.7 mm) 20 (6.7 mm) 14-16
Gore 18 (6.0 mm) 18 (6.0 mm) 20 (6.7 mm) 12-18
Cook 18 (6.0 mm) 20 (6.7 mm) 22 (7.3 mm) 14-16Midterm Changes in Renal Function Following Snorkel Repair of
Juxtarenal Aneurysms
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Objectives: The snorkel approach for EVAR has shown to be a safe
and viable alternative to open repair for juxtarenal AAAs with good short-
term outcomes. Concerns about long-term durability and renal branch
patency of this technique have been raised with increasing availability of
fenestrated devices. We sought to evaluate renal function changes in patients
undergoing Sn-EVAR.
Methods: Patients who underwent Sn-EVAR from 2009-2012 were
included in this analysis. Creatinine values were obtained throughout the
patient’s pre-, peri-, and postoperative course. GFR was estimated using
the simpliﬁed modiﬁcation of diet in renal disease (MDRD) formula.Chronic renal insufﬁciency was deﬁned as pre-op serum creatinine >1.5
mg/dL. Postoperative renal dysfunction was stratiﬁed by two methods,
creatinine increase >0.5 mg/dL as well as with the previously validated
RIFLE classiﬁcation system utilizing GFR.
Results: 43 consecutive patients underwent Sn-EVAR (32 double
renal, 11 single renal) for jAAA. Mean follow-up time was 23 months.
Mean aneurysm size was 6.6 cm (range, 5.3-10.5 cm) and unable to be
treated with standard EVAR (mean neck length 1.7 mm). Six (13%) patients
had baseline chronic renal insufﬁciency. 75 renal snorkel stents were success-
fully placed with a 2-year primary patency of 95%. Mean baseline, maximum
postoperative, and latest follow up creatinine were 1.20, 1.62, and 1.45
respectively (P < .05). Mean baseline, maximum postoperative, and latest
follow up GFR were 57.4, 46.3, and 49.5, respectively (P < .05). Seven
patients (15.6%) developed chronic renal insufﬁciency based on creatinine
levels alone. Thirteen patients (29%) had >25% decline in GFR (mild renal
dysfunction), while two patients (4%) had a >50% decline (moderate renal
dysfunction). No patients had >75% decline in GFR (severe renal dysfunc-
tion) or required long term dialysis. All-cause mortality at latest follow-up
was 11%.
Conclusions: Midterm renal function changes for patients under-
going Sn-EVAR for jAAAs is favorable compared to published reports
of open repair and f-EVAR. The majority of patients did not experience
decline in renal function, and those that did have changes were classiﬁed
as mostly mild. Sn-EVAR should continue to be considered an endovas-
cular option for complex AAAs, especially in high-risk operative
candidates.
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Objectives: Tortuous, highly calciﬁed, severely stenotic or occluded
iliac vessels may render endovascular repair of aortic aneurysms problematic
or unsafe. Retroperitoneal conduit is a solution to this problem but has
surgical risks and is not feasible in highly calciﬁed vessels (Fig 2, A). A prom-
ising alternative is the “Pave and Crack” technique. This typically consists of
10-12 mm intraluminal conduit (endoconduit) deployment in iliac vessels
with coverage of the internal iliac artery (IIA). We present 3 cases from
our institution and propose a method of appropriately selecting endocon-
duit diameter that addresses the increasing variety of aneurysm exclusion
devices.
Methods and Results: Case 1: A 7.4-mm (minimum diameter) left
CIA and 6.8-mm right CIA were predilated to 9 mm and lined with
10-  5-mm Viabahn and 8-  39-mm Atrium stent grafts, respectively.
After 10-mm balloon dilation of these endoconduits, a 22F bifurcated
device was deployed for successful aneurysm exclusion.
Case 2: A 6.5 mm diameter EIA was predilated to 8 mm and lined with
a 10-  50-mm Viabahn stent graft that was postdilated to 9 mm. A 22F
aortouniliac device was successfully passed and deployed, but the endocon-
duit was inadvertently pushed into the aneurysm sac and subsequently
excluded as “endotrash.”
Case 3: A severely stenotic CIA (5.8 mm) and EIA (4.2 mm) were
initially predilated to 7 mm and 5 mm, respectively, and subsequently lined
with 10-  5-mm and 10-  10-mm Viabahn stents, sparing the IIA. After
postdilation to 10 mm, a 24F Medtronic bifurcated device passed through
these endoconduits for successful aneurysm exclusion.
Conclusions: These cases reveal two key points: the relevance of
endoconduit diameter selection and the safety of maintaining internal iliac
